Treatment of acromegaly with oral octreotide

Ilan Remba-Shapiro; Lisa B Nachtigall

doi:10.1016/j.beem.2024.101888

Treatment of acromegaly with oral octreotide

Best Pract Res Clin Endocrinol Metab. 2024 Feb 22:101888. doi: 10.1016/j.beem.2024.101888. Online ahead of print.

Authors

Ilan Remba-Shapiro¹, Lisa B Nachtigall²

Affiliations

¹ Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: iremba@mgh.harvard.edu.
² Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: lnachtigall@partners.org.

PMID: 38443224
DOI: 10.1016/j.beem.2024.101888

Abstract

Acromegaly is a rare disease caused by a growth hormone excess, usually due to a secreting pituitary adenoma. Somatostatin receptor ligands (SRL) are the mainstay of medical therapy for patients with acromegaly who fail to achieve biochemical control post-operatively or are not eligible for surgical treatment. SRLs are typically administered as monthly injections and have shown to be effective in maintaining biochemical and radiological control of acromegaly. However, these injections may cause local adverse events and are associated with increased psychological burden in some patients. Oral octreotide provides a new alternative for patients responding to injectable SRLs. This new formulation has shown to have similar safety and efficacy profiles compared to injectable SRLs and may be a preferable option for some patients with acromegaly. The aim of this review is to provide an overview of the role of oral octreotide in the management of acromegaly.

Keywords: IGF-1; acromegaly; growth hormone; oral octreotide; somatostatin receptor ligands.

Publication types

Review